Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Scott Williams, Ian D. Davis, Christopher Sweeney, Martin R. Stockler, Andrew James Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, Nicola Jane Lawrence, Ray McDermott, Paul J. Kelly, Olwyn Deignan, Simon Hughes, Valerie Fonteyne, Bertrand F. Tombal, Paul L. Nguyen, Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Institutions: Peter MacCallum Cancer Centre, Eastern Health, Monash University, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, The University of Sydney, Cancer Trials Ireland, Cork University Hospital, Guy's and St Thomas' NHS Foundation Trust, Ghent University Hospital, Cliniques Universitaires Saint-Luc, Harvard University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4239807907